Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

Status: Unknown

Conditions: Epilepsy

Treatments: Drug: eslicarbacepine

Study type: Observational

Funder types: Other

Identifiers

NCT02573272

FPS-ESL-2105-01

Details and patient eligibility

About

Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.

Enrollment: 204 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients over 18 years
• patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests.
• patients with stable and identifiable antiepileptic treatment during the last two years.
• patients according to the investigator are able to provide clinical data necessary for the development of the study
• Patients who signed informed consent

Exclusion criteria

• Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.

Trial design

204 participants in 1 patient group

Epileptic patients with AEDs and eslicarbacepine

Treatment:

Drug: eslicarbacepine